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Objectives: To compare the clinical anesthetic efficacy of 0.5% bupivacaine and 4% articaine (both with 1:200.000 
adrenaline) for anterior maxillary infiltration in healthy volunteers. 
Material and methods: A triple-blind split-mouth randomized clinical trial was carried out in 20 volunteers. A 
supraperiosteal buccal injection of 0.9 ml of either solution at the apex of the lateral incisor was done in 2 appoint-
ments separated 2 weeks apart. The following outcome variables were measured: latency time, anesthetic efficacy 
(dental pulp, keratinized gingiva, alveolar mucosa and upper lip mucosa and tissue) and the duration of anesthetic 
effect. Hemodynamic parameters were monitored during the procedure.
Results: Latency time recorded was similar for both anesthetic solutions (p>0.05). No statistically significant 
differences were found in terms of anesthetic efficacy for dental pulp, keratinized gingiva or alveolar mucosa. 
Articaine had a significant higher proportion of successful anesthesia at 10 minutes after infiltration in lip mucosa 
and  lip skin (p=0.039). The duration of anesthesia was 336 minutes for bupivacaine and 167 minutes for articaine. 
(p<0.001). No significant hemodynamic alterations were noted during the procedure.
Conclusions: Articaine and bupivacaine exhibited similar anesthetic efficacy for maxillary infiltrations. The dura-
tion of anesthesia was longer with the bupivacaine solution, but lip anesthesia was better with articaine.
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Introduction
Bupivacaine is a long-acting local anesthetic that has 
been marketed for dental use since 1971. Various stud-
ies have been published evaluating the clinical efficacy 
of bupivacaine, and although it does not differ much 
chemically from mepivacaine, another anesthetic from 
the same group, bupivacaine has clearly distinct clinical 
properties. Compared with other local anesthetics, the 
main advantages of bupivacaine are longer anesthetic 
effect and prolonged residual analgesia. The main con-
cern is its potential cardiovascular toxicity (1).
Articaine was synthesized in 1969, but it was not until 
1976 that it would be introduced for clinical dentistry. 
It was first marketed in Germany and subsequently 
throughout Europe and Canada, and in 2000, in the 
United States. It has some unique chemical character-
istics: it is the only amide local anesthetic that contains 
a thiophene ring and no aromatic ring. Besides, it is the 
only widely used amide local anesthetic that contains an 
additional ester ring within its chemical structure (1-3).
Several reports (4-8) have evaluated and compared 
bupivacaine versus other local anesthetics, especially 
for lower third molar removal. However, few stud-
ies comparing bupivacaine and articaine have been 
published, the present study being the first clinical 
trial comparing these two anesthetics for maxillary 
infiltrations.
The aim of this work was to compare the clinical anes-
thetic efficacy of 0.5% bupivacaine and 4% articaine, 
both with 1:200.000 adrenaline for maxillary infiltra-
tions. A secondary objective was to detect any hemody-
namic alterations after the anesthetic injection.
Materials and Methods
A triple-blind randomized controlled clinical trial 
(RCT) was conducted in healthy student volunteers 
at the Dental School of the University of Barcelona 
(Spain) from July 2009 to January 2010. Participants 
were recruited using advertisements describing the ob-
jective of the study, the inclusion criteria and payment 
for participation. The research protocol was according 
the Helsinki’s declaration and was approved by the in-
stitutional review board (Ethics Committee for Clinical 
Investigation of the Dental School of the University of 
Barcelona). The clinical trial was conducted follow-
ing the guidelines of the CONSORT statement (9). The 
inclusion criteria were healthy volunteers (ASA I) be-
tween 18 to 30 years old; with absence systemic disease, 
no background of medication hypersensitivity or preg-
nancy; no toxic habits (including alcohol abuse, smok-
ing or regular cannabis smoking or other drug use); 
absence of routine medication use; absence of adverse 
reaction to local anesthetics; absence of dental diseases 
(tooth decay or other abnormalities), tooth restorations, 
traumatic lesions, dental hypersensitivity or periodontal 
disease for all teeth under study; positive pulp vitality 
tests in all teeth under study; absence of acute or chron-
ic infections in the oral and maxillofacial area.
The exclusion criteria were use of any medication for 15 
days prior to study; use of local anesthetics in the oral 
and maxillofacial area for 15 days prior to study; heart 
rate lower than 50 or higher than 90 beats/min; latency 
time longer than 3 minutes during infiltration. In this 
case, infiltration is repeated in another session to rule 
out the possibility of errors in anesthesia administra-
tion; if a volunteer drops out.
The RCT had a split-mouth, cross-over design. Randomi-
zation was based on a sequence generated by Laboratori-
os Inibsa, Barcelona, Spain. Both solutions were encoded 
so that the surgeon performing the anesthesia infiltration, 
the monitor recording the variables and the volunteer 
could not identify the anesthetic solution used. 
At the first appointment, we completed a thorough an-
amnesis and clinical examination and checked for fulfil-
ment of inclusion criteria. We provided an explanation 
of details of the study and patients signed an informed 
consent form. 
During the second appointment, infiltrative anesthesia 
was performed on an upper lateral incisor with the con-
tralateral canine as the control. At the third appointment 
sides were changed: anesthesia of the upper lateral in-
cisor not selected during the second appointment and 
contralateral canine as the control. The same surgeon 
(MAVP) performed all anesthetic infiltrations and the 
outcome variables and hemodynamic values were regis-
tered by the same examiner (MSP). Both appointments 
were spaced at least 2 weeks apart.
Anesthetic solutions under study were bupivacaine 
0.5% and articaine 4%, both with 1:200.000 adrenaline, 
and were specifically prepared by Laboratorios Inibsa, 
Barcelona, Spain. For anesthesia infiltration we used 
a Uniject® syringe (Laboratorios Normon, Madrid, 
Spain) with a short 27G Monoprotect XL® needle of 
25 mm length (Laboratorios Inibsa, Barcelona, Spain). 
Volunteers were placed in the supine position with chest 
at an angle of 30 degrees. After negative aspiration was 
performed, 0.9 mL of the anesthetic solution was depos-
ited over a 30-seconds time period.
-Outcome variables
Latency time: it was subjectively assessed by the first 
reported sensation of upper lip numbness. We classified 
the time interval between needle removal and numbness 
onset in 3 categories: immediate after needle removal, 
after less than 30 seconds or after 30 seconds or more. 
Soft tissue anesthesia: we determined anesthetic ef-
ficacy on the attached gingiva, alveolar mucosa upper 
lip mucosa and lip skin with a sharp 4/6 Maillefer ex-
ploratory probe (Dentsply Maillefer, Tulsa, USA). We 
considered anesthesia effective when patient did not no-
tice any pain when the exploratory probe was pressed 
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with a light force 3 consecutive times. In case of pain or 
doubtful answer, anesthetic efficacy was judged to be a 
failure. The values were recorded at 5, 10, 15, 20, 25, 30, 
35, 40, 50 and 60 minutes after anesthesia infiltration.
Pulpal anesthesia: We determined the pulp vitality us-
ing the Elements Diagnostic Unit and Apex Locator 
(SybronEndo Corporation, Orange, USA). During the 
first appointment, baseline information was obtained 
for both lateral incisors and upper canines. On the 2 
subsequent visits, pulpal anesthesia of the anesthetized 
lateral incisors was assessed together using the contral-
ateral canines as a negative control. We considered pul-
pal anesthesia successful if electric pulp tester readings 
were higher than 60 without eliciting pain. Values were 
recorded at 5, 10, 15, 20, 25, 30, 35, 40, 50 and 60 min-
utes after anesthesia infiltration.
Total duration of anesthesia (soft tissues): time of infil-
tration injection was recorded for each procedure. The 
duration of lip numbness was assessed by training the 
subjects to report when soft tissue anesthesia wore off 
and register the time. We registered the time interval 
between anesthetic infiltration and cessation of subjec-
tive sensation of lip numbness. 
The patient was assessed during 60 minutes. After, pa-
tients were discharged and were instructed to report the 
time the anesthesia had worn off. 
-Hemodynamic parameters
Baseline hemodynamic parameters (heart rate, systo-
lic blood pressure, diastolic blood pressure and oxygen 
saturation) were recorded during the first appointment 
using a Guardian BPM-730 M monitor (Megos-Son-
médica, Barcelona, Spain). On the 2 subsequent visits, 
they were assessed 1 minute before and 1 minute after 
anesthesia infiltration, and then at 5, 15, 30 and 60 min-
utes after infiltration. 
-Statistical analysis
A descriptive, bivariate statistical analysis was per-
formed using the SPSS version 14.0 statistical package 
(SPSS; SPSS Inc; Chicago, USA). Intrasubject variabil-
ity was compared by Student’s t-test, McNemar’s test 
and Analysis of Variance (ANOVA). Intersubject vari-
ability was assessed by Student’s t-test and Spearman’s 
test. Statistical significance value was set as p<0.05.
Results
A total of 33 volunteers agreed to participate in the 
study. Seven were excluded as they were allergic to 
some medication, 2 because of negative responses ob-
tained for pulp vitality test for some teeth under study 
and other 4 for incompatibility with work hours (Fig. 1). 
The total sample was 20 volunteers (15 women and 5 
men) with a mean age of 22.75 year (SD=2.15). Hemo-
dynamic parameters recorded during the whole proce-
dure were within the standard values (Table 1). No sta-
tistically significant differences were found in terms of 
systolic blood pressure, diastolic blood pressure, heart 
rate and oxygen saturation for both anesthetic solutions 
during the intervals under study (ANOVA test p>0.05). 
No complications connected with the anesthesia admin-
istration were reported.
Latency time for soft tissue anesthesia in both anesthetic 
solutions did not show statistically significant differenc-
es. In the bupivacaine group, 80% volunteers reported 
that anesthesia was felt before withdrawing the needle 
10% a period shorter than 30 seconds and the remaining 
10% longer than 30 seconds. Articaine showed similar 
results as 85% felt numbness before withdrawal of the 
needle, 10% described a period shorter than 30 seconds 
and 5% longer than 30 seconds.
Both solutions had a similar efficacy for pulpal an-
esthesia. In the two groups, 100% success rate of anes-
thetic efficacy was not obtained during the procedure. 
Bupivacaine seemed to be effective in more cases from 
minute 15 until minute 60, but these differences were 
not significant (Fig. 1).
The anesthesia administration on keratinized gingiva 
and alveolar mucosa did not report statistically signifi-
cant differences for both solutions. As well as in pulpal 
anesthesia, bupivacaine showed a greater anesthetic ef-
ficacy compared with articaine, from minute 15 (kerati-

BASAL 1 minuto 5 minutos 15 minutos 30 minutos 60 minutos 
A B A B A B A B A B A B 
FC 73,75 70,80 69,30 69,40 72,80 72,55 68,70 70,40 64,55 65,05 65,05 67,30 
TAS 111,6 113,25 110,6 112,75 109,25 112,5 109,75 110,10 109,15 112,3 107,65 111,5 
TAD 64,85 67,15 63,75 66,75 63,20 69 62,55 63,35 62,95 66,40 63,80 60,80 
SaO2 99,2 99,10 99,25 99,20 99,10 99,20 99 99 99,25 99,10 99,20 99,15 
Table 1. Hemodynamic parameters recorded at each time of examination. Column A is the articaine solution and column 
B to the solution with Bupivacaine. HR = heart rate (beats / min), SBP = systolic blood pressure (mmHg), DBP = diastolic 
blood pressure (mmHg), SaO2 = oxygen saturation (%).
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nized gingiva) and minute 20 (alveolar mucosa) until 
the end of procedure (Fig. 2).
In contrast, lip mucosa did report statistically signifi-
cant differences at 10 minutes after infiltration (Figure 
3). At that moment, anesthetic efficacy of articaine was 
95% and bupivacaine only 60% for the volunteers re-
porting effective anesthesia (McNemar’s test p=0.039). 
Similar differences were also found for lip skin. Ar-
ticaine proved greater anesthetic efficacy (90%) at 10 
minutes compared with bupivacaine (55%) (McNemar’s 
test p=0.039). At 15 and 20 minutes after anesthesia in-
filtration, differences were obtained for both anesthetic 
solutions, although they were no statistically significant 
(p=0.063). For the lip mucosa and lip skin, articaine 
exhibited greater efficacy during the whole procedure 
(Fig. 3).
Total duration of anesthesia (soft tissues) reported by 
participants was 336.00 minutes (SD=166.46) for bupi-
vacaine, whereas articaine obtained lower results, with 
a mean duration of 163.45 minutes (SD=57.48). Dif-
ferences found were statistically significant (t-Student 
p=0.000).
Discussion
Latency time, anesthetic efficacy and duration of an-
esthesia are the main parameters studied in other re-
ports that use a similar study design. However, it is dif-
ficult to compare results as dosages, anesthetics, use of 
vasoconstrictors and methods differ (10). 
Latency time was calculated as the interval between in-
jection and the time when anesthesia is achieved. It repre-
sents a key factor when choosing the anesthetic solution. 
It can be determined using different calculations and will 
vary according to the areas under study or treatment. In 
the present study, the latency time was subjectively eval-
uated by participants who reported upper lip numbness. 
Our results are similar to those obtained by Kennedy et 
al. (11) who reported a latency time of 0.86 minutes for 
0.5% ropivacaine used for lip anesthesia (assessed as well 
according to the onset of lip numbness). Gross et al. (12) 
did also evaluate the anesthetic efficacy of 0.5% bupi-
vacaine with 1:200.000 epinephrine in maxillary lateral 
incisors. The result, though, was 3.19 minutes (SD=3.72) 
as results were obtained for pulpal anesthesia. Accord-
ing to Evans et al. (13), the onset of pulpal anesthesia 
was 2.5 minutes (SD=1.22) in maxillary lateral incisors 
Fig. 1. Onset of pulpa anesthesia Fig. 2. A) Anesthesia efficacy on keratinized gingiva. B) Anesthesia efficacy on alveolar 
mucosa.
Fig. 3. A) Anesthesia efficacy on lip mucosa. B) Anesthesia efficacy on upper akin.
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and 3 minutes (SD=1) for Vähätalo et al (14), although 
adrenaline concentrations were different:1:100.000 and 
1:200.000 respectively.
The main difference between our study and earlier 
works (11-14) is that we determined the efficacy of soft 
tissue anesthesia as well as pulpal anesthesia. Thus, we 
were able to find differences in both anesthetic solutions 
that could go undetected otherwise. Furthermore, the 
use of a triple-blind, split-mouth, RCT design optimized 
sample size. In addition, the administration of just 0.9 
mL of anesthetic solution helped to reduce the duration 
of anesthesia.
With regards the evaluation of pulpal anesthesia, 
Dreven et al. (15), and Certosimo and Archer (16) con-
cluded that pulpal anesthesia was successful when read-
ings of 80 were obtained from the electric pulp tester 
because that lower readings were associated with pain 
during restoration. This criterion was not been included 
in our study for ethical reasons, as all participants were 
healthy volunteers, anesthesic dosage was low (0.9 mL) 
and the main objective was to compare the efficacy of 
both solutions with no need for further treatment. For 
this reason, a 60 reading obtained by the pulp tester was 
considered enough.
No statistically significant differences were found in the 
present study for both solutions used for anesthesia of 
dental pulp, keratinized gingiva and alveolar mucosa. 
Besides, no statistical differences were found com-
pared with other authors in terms of anesthetic efficacy 
achieved at 5 minutes after infiltration. In our study, 
bupivacaine showed 70% of pulpal anesthesia at 5 min-
utes, whereas Gross et al (12) the success of the infiltra-
tion of the bupivacaine solution was 78% and according 
to Kennedy et al. (11), 80%. A lower result may be asso-
ciated with the use of a lower dose of anesthetic solution 
(0.9 mL). Articaine showed same result at 5 minutes, 
70%. Evans et al. (13) reported a result of 88%. It is 
important to underline that such percentages may vary 
depending on the methodology used for analysis and the 
use of different anesthetic solutions. For example, Gross 
et al. (12) reported that the proportion of successful an-
esthesia in lateral incisors after maxillary infiltration 
with lidocaine solution was 97%, while  Evans et al (13), 
using a similar methodology reported only a  62%. 
When comparing the success rate for lip mucosa and lip 
skin, articaine reported higher results during the whole 
procedure. However, bupivacaine did not show similar 
or greater results. Anesthetic technique involved para-
apical supraperiostic infiltration of upper lateral incisor, 
thus anesthetic effect on lip mucosa and lip skin should 
be regarded as the consequence of anesthetic solution dif-
fusion to the areas far away from infiltration area. The 
fact the bupivacaine did not offer similar success rates to 
those obtained by articaine and the statistical differences 
found at minute 10 may be connected with the results re-
ported by some authors (6, 17-19), as bupivacaine has a 
low diffusion rate into  soft tissues. Because bupivacaine 
has high protein binding, the above results may be justi-
fied and latency time may be prolonged as the diffusion 
into the infiltrated area may be delayed.
Furthermore, the high protein binding of bupivacaine 
may be responsible for a prolonged anesthesia on 
soft tissues that varies from 6-12 hours. In our study, 
bupivacaine reported a duration of anesthesia time of 
336 minutes (SD=166.46) whereas articaine showed 
lower results, with a mean time of 163.45 (SD=57.48). 
Kennedy et al. (11) reported a duration of lip anesthesia 
of 512.25 minutes (SD=179.76) while Gross et al. (12) 
obtained results similar to ours, with a duration of 383 
minutes (SD=169).
The use of bupivacaine as well as the rest of local an-
esthetics is not free of risks. In the present study, no 
significant between both solutions have been found in 
terms of hemodynamic parameters. Besides, no adverse 
reactions associated with the use of bupivacaine have 
been reported. However, the amount of anesthetic so-
lution was 0.9 mL for young, healthy individuals and 
therefore with low risk of cardiovascular complications. 
Although several deaths have been associated with the 
use of bupivacaine, most of such cases referred were 
not dental treatments and the dosages used were higher 
than the ones widely used in Dentistry.
Bacsik et al. (4) published a comprehensive review of 
the literature in order to determine the toxicity from 
anesthetics such as bupivacaine. They reported that the 
total dosage that can be administered is lower compared 
to the rest of local anesthetics belonging to the amide 
group. However, the low dosage will not substantially 
change the final number of cartridges that can be used, 
as concentration for the rest of amide local anesthetics 
is higher (articaine 4%, lidocaine 2%, mepivacaine 3%) 
compared with bupivacaine 0.5%. 
In conclusion, the anesthetic efficacy obtained for both 
solutions in maxillary infiltration in terms of pulpal 
anesthesia, keratinized gingiva and alveolar mucosa is 
similar. However, lip mucosa was better anesthetized 
with articaine, suggesting that difussion of bupivacaine 
could be worse. The concentration and dose used for 
both solutions did not produce any noticeable hemody-
namic alterations.
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